Target

CD47

Leukocyte surface antigen CD47

9open trials
27trials in total
138publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Publication
Circular RNA CD47 triggers the tumor progression and immunoregulation of non-small cell lung cancer via miR-889-3p/COPS5-mediated PD-L1 deubiquitination.
31 Oct 2026· 3 Biotech· PUBMED
Publication
CD47 blockade augments anti-GD2 driven phagocytosis in vitro but fails to improve in vivo efficacy in immunocompetent, chemoresistant neuroblastoma preclinical models.
27 Oct 2026· PloS one· PUBMED
Publication
Serine protease inhibitor A3 is a soluble SIRPα ligand that suppresses inflammation and antitumor immunity.
22 Oct 2026· Nature immunology· PUBMED
Publication
CD47 fuels intestinal fibrosis by inducing fibroblast phagocytic evasion and represents a therapeutic target.
20 Oct 2026· Cell reports. Medicine· PUBMED
Publication
Enhancing neoadjuvant immunotherapy for locally advanced rectal cancer via an injectable thermosensitive hydrogel system with multipathway macrophage immunomodulation.
7 Oct 2026· Biomaterials· PUBMED
Publication
A Patient-Derived Screen Identifies HDAC Inhibitors as Enhancers of Phagocytosis and Potent Immunotherapy Partners.
5 Oct 2026· Cancer immunology research· PUBMED
Publication
A reciprocally masked anti-CD47/IL-2 fusion protein promotes antitumor immunity and limits systemic toxicity.
5 Oct 2026· Cancer immunology research· PUBMED
Publication
Dual-Targeting of ER Stress and the CD47-SIRPα Axis via an In Situ Hydrogel Prevents Postoperative Glioblastoma Recurrence.
4 Oct 2026· Small (Weinheim an der Bergstrasse, Germany)· PUBMED
Publication
Prognostic Significance of CD47 and DHX9 in Metastatic Rectal Cancer.
3 Oct 2026· Medical sciences (Basel, Switzerland)· PUBMED
Publication
In Vivo Immunoscoring Technique to Monitor Anti-CD47 Immunotherapy Efficacy in Triple-Negative Breast Cancer.
1 Oct 2026· Cancer medicine· PUBMED
Publication
Type 1 diabetes SIRPG risk variants increase SIRPγ expression and CD47 loss enhances CD8+ T cell cytotoxicity.
1 Oct 2026· NPJ autoimmunity· PUBMED
Publication
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.
1 Oct 2026· Cancer· PUBMED
Publication
Clinical implications of CD47 and programmed death-ligand 1 expression in predicting the therapeutic response of immune checkpoints in advanced nonsmall-cell lung cancer.
29 Sept 2026· Journal of cancer research and therapeutics· PUBMED
Publication
CD47-SIRPα as a Therapeutic Target in Sarcoma: A Systematic Review of Expression, Preclinical, and Clinical Evidence.
27 Sept 2026· Biomedicines· PUBMED
Publication
Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer.
26 Sept 2026· Biomedicines· PUBMED
Publication
Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200.
11 Sept 2026· Frontiers in oncology· PUBMED
Preprint
A Distal Super-Enhancer Regulates CD47 Expression and Promotes Macrophage-Mediated Phagocytosis of Ovarian Cancer Cells.
10 Sept 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Chemotherapy-Activated GSK3β-DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma.
29 Aug 2026· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publication
ROMO1 and CD47 in Cervical Cancer: Parallel but Independently Regulated.
25 Aug 2026· Current issues in molecular biology· PUBMED
Publication
Alantolactone inhibits T-cell lymphoma progression by suppressing CD47 expression via the PI3K/AKT and ERK signaling pathways.
23 Aug 2026· Apoptosis : an international journal on programmed cell death· PUBMED
Publication
UBA1 enhances phagocytosis by suppressing CD47 expression in small cell lung cancer.
20 Aug 2026· Frontiers in oncology· PUBMED
Publication
Targeting a candidate stromal immune checkpoint: a cellular senescence signature identifies COMP⁺ cancer-associated fibroblasts associated with CD8⁺ T-cell exclusion via a predicted COMP-CD47 axis in colorectal cancer.
20 Aug 2026· Journal of advanced research· PUBMED
Publication
Teniposide facilitates macrophage phagocytosis by targeting the CD47-SIRPα axis and the candidate protein TRIM54 in lung cancer.
19 Aug 2026· Biochimica et biophysica acta. Molecular basis of disease· PUBMED
Publication
CD47 Aptamer-Decorated Fluorescent POSS Hybrid Nanoparticles as a Biohybrid Interface for Probing Prostate Cancer-Macrophage Interactions.
18 Aug 2026· Biomimetics (Basel, Switzerland)· PUBMED
Publication
Tumor size limits macrophage activation and imaging response to CD47 blockade in osteosarcoma.
17 Aug 2026· Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie· PUBMED
Publication
CD47 promotes myeloma cell growth through JAK-STAT3/MYC signalling and is targetable by ruxolitinib.
14 Aug 2026· British journal of haematology· PUBMED
Publication
CD47 and FOXP3+ Regulatory Immunity in Colorectal Cancer: A Conceptual Framework for Coordinated Immunosuppression.
13 Aug 2026· Cancers· PUBMED
Publication
A potent anti-CD47 antibody decoupling anti-tumor efficacy from hematotoxicity.
11 Aug 2026· International immunopharmacology· PUBMED
Publication
Notch-1 induces M2 polarization of tumor-associated macrophages via the YAP/EZH2/FOXD1/CD47 signaling axis, thereby driving non-small cell lung cancer progression.
10 Aug 2026· Frontiers in medicine· PUBMED
Publication
In Vivo Analysis of Neuroblastoma Targeting Potential of aGD2-SIRPα Fusion Antibodies for Local CD47 Blockade.
4 Aug 2026· Molecular cancer therapeutics· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error